Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis

  •  Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1

  • CHMP opinion is based on two Phase III ASCLEPIOS studies that met the primary endpoints where Kesimpta showed a reduction of the annual relapses by over 50% versus teriflunomide and achieved more than 30% relative risk reduction of 3-month confirmed disability progression (CDP) 1

  • In a post hoc analysis, nearly …
/by

Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine

  • First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine
  • Initial agreement signed with BioNTech to use Novartis manufacturing plant in Stein, Switzerland, to support production of mRNA COVID-19 vaccine
  • Production to commence in the second quarter for estimated delivery commencing in the third quarter 2021

Basel, January 29, 2021 — Novartis announced …

/by

Novartis renews WHO medicine donation pledge with aim of ending leprosy

  •  Novartis leprosy medicine donation program with WHO extended to 2025
  • Program has already treated over 7 million patients since 2000
  • New evidence from contact tracing and preventive treatment program shows route to accelerate elimination

Basel, January 29, 2021 — A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 …

/by